ITK (IL2-inducible T-cell Kinase) Drug Discovery Landscape & Assay Solutions
- By admin
- 14 Aug 2026
- Comments
High-Purity Reagents for Tec Family Kinase Selectivity & T Cell Signaling Research
IL2-inducible T-cell kinase (ITK) is a critical Tec family tyrosine kinase mediating T cell receptor (TCR) signaling, Th2 differentiation, and mast cell activation. As a pivotal intracellular target for autoimmune diseases (lupus, psoriasis, IBD, SLE, atopic dermatitis) and T cell malignancies (T-ALL, T-cell lymphoma), ITK inhibitors require rigorous selectivity profiling against homologous kinases (BTK, BMX, Tec, TXK) and robust cellular validation tools. TarMart provides sequence-verified recombinant proteins, lentiviral systems, and RNAi validators to support structure-based drug design and mechanism-of-action studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ITK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Kinase Domain) | ITK Kinase Domain (Glu363-Gly619). High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. ATP-binding site intact. | View ITK Products |
| Antigen (Full-length) | ITK Full-length Protein (1-620 aa). HEK293 Expressed. Includes PH, TH, SH3, SH2 domains for regulatory studies. | View ITK Products |
| Gene Delivery | ITK Promise-ORF / Lentivirus. Full-length ORF with C-terminal tag. For stable cell line construction in Jurkat or primary T cells. | View ITK Products |
| Benchmark Ab | Anti-ITK Detection mAb (Total / Phospho-specific). Recombinant research-grade control for Western, Flow cytometry, and cellular assays. | View ITK Products |
| Validator | ITK siRNA Set (3 unique sequences). For knockdown verification and specificity control in T cell activation assays. | View ITK Products |
| Selectivity Panel A | BTK Kinase Domain. Tec family homolog for selectivity screening. Mass spec verified. | View BTK Products |
| Selectivity Panel B | TEC Kinase Domain. Subfamily off-target liability control. | View TEC Products |
| Selectivity Panel C | TXK Kinase Domain. Synergistic T-cell kinase and off-target counter-screen. | View TXK Products |
| Pathway Partner | LCK Kinase. Upstream SRC family kinase in TCR signaling. For epistasis studies. | View LCK Products |
| Related Target | ZAP70. Synergy with ITK in TCR proximal signaling. For combination studies. | View ZAP70 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Tec Family Selectivity (BTK/TEC/BMX/TXK cross-reactivity) | Homolog Panel Proteins strictly verified by mass spec; Same expression system (HEK293) ensures consistent glycosylation and folding for accurate SAR. |
| Kinase Activity Verification | High-activity recombinant ITK expressed to preserve functional conformation. Sequence Verified. High purity (>95%) minimizes contaminant phosphorylation. |
| Cross-species PK/PD Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. Sequence Verified. |
| Drug Resistance Profiling (gatekeeper & activation loop mutants) | ITK mutant recombinant proteins (e.g., M438T, A542T, C442S) for pre-emptive resistance assays. Endotoxin Controlled. Custom synthesis available. |
| Cellular Target Engagement & False Positives | Validated siRNA included for specificity checks. Lentivirus (high titer >10^8 TU/ml) for stable knockdown/overexpression cell lines. |
| Autophosphorylation Status Control | Theoretical MW validation by SDS-PAGE; Pre-kinase treatment options available. |
| Lack of Controls | Clinical Benchmark Antibodies included for reliable assay baselines. |
Live ITK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The ITK inhibitor landscape is transitioning from early-stage oncology (T-ALL, T-cell lymphoma) toward autoimmune indications (lupus, psoriasis, IBD, SLE, atopic dermatitis, rheumatoid arthritis) where selective T cell suppression offers advantages over broad immunosuppression. Current clinical leaders include Bristol-Myers Squibb (BMS-986195, reversible inhibitor in Phase 2 for SLE/psoriasis) and Corvus Pharmaceuticals (CPI-818, covalent inhibitor targeting Cys442 in Phase 1/2 for T-ALL and solid tumors, also exploring combination with PD-1/PD-L1). Sanofi (via Principia) and emerging biotechs are advancing highly selective non-covalent inhibitors and PROTAC degraders to overcome off-target toxicities and resistance mutations. The next wave of differentiation emphasizes BTK-sparing selectivity (>100-fold over BTK to preserve humoral immunity), brain-penetrant compounds for neuroinflammatory conditions, reversible binding kinetics, and combination strategies with checkpoint inhibitors to modulate the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent, irreversible) | Corvus Pharmaceuticals (CPI-818) | Refractory T-ALL, T-cell lymphoma, autoimmune | Cysteine-to-Serine Mutant ITK (C442S) for mechanistic validation; Kinase Activity Assay |
| Small Molecule (Non-covalent, reversible) | BMS, Sanofi, Principia | Psoriasis, SLE, RA, IBD, asthma | Selectivity Assay (need TEC family homolog panel: ITK vs BTK/TEC/TXK) |
| PROTAC / Degrader | Emerging Biotechs | Refractory autoimmune, oncology | Full-length ITK (1-620 aa) for ternary complex formation; Lentivirus for cell permeability studies |
| Allosteric Modulator | Academic / Preclinical | Th2-driven asthma, atopic dermatitis | SH2/SH3 domain proteins for PPI disruption assays |
深入技术要点：ITK结构与突变
ITK contains functional domains: PH (pleckstrin homology), SH3, and SH2, as annotated in UniProt Q08881. Key somatic mutations identified include a metastatic melanoma-derived mutation (dbSNP:rs1753502279) and another in metastatic melanoma (VAR_041711), as well as a common variant rs17054374. These mutations underscore the relevance of ITK in oncogenesis and drug resistance profiling. TarMart offers custom mutant constructs for resistance mechanism studies.